FY2025 Earnings Estimate for Puma Biotechnology, Inc. Issued By Zacks Research (NASDAQ:PBYI)

Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Equities research analysts at Zacks Research lowered their FY2025 earnings per share (EPS) estimates for Puma Biotechnology in a research note issued to investors on Wednesday, April 3rd. Zacks Research analyst K. Shah now anticipates that the biopharmaceutical company will post earnings of $0.27 per share for the year, down from their prior forecast of $0.30. The consensus estimate for Puma Biotechnology's current full-year earnings is $0.29 per share. Zacks Research also issued estimates for Puma Biotechnology's Q4 2025 earnings at $0.08 EPS and Q1 2026 earnings at $0.08 EPS.

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last released its earnings results on Thursday, February 29th. The biopharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.07). The firm had revenue of $72.20 million for the quarter, compared to analyst estimates of $73.22 million. Puma Biotechnology had a return on equity of 58.21% and a net margin of 9.16%.

PBYI has been the topic of several other research reports. StockNews.com upgraded Puma Biotechnology from a "hold" rating to a "buy" rating in a report on Tuesday. HC Wainwright cut their price objective on Puma Biotechnology from $8.00 to $7.00 and set a "buy" rating on the stock in a report on Friday, March 1st.

Puma Biotechnology Trading Up 2.7 %

NASDAQ PBYI traded up $0.15 on Friday, hitting $5.66. 405,308 shares of the company were exchanged, compared to its average volume of 610,403. The company's 50 day moving average price is $5.61 and its 200-day moving average price is $4.28. The company has a debt-to-equity ratio of 1.23, a current ratio of 1.57 and a quick ratio of 1.50. The firm has a market capitalization of $272.85 million, a P/E ratio of 12.30, a price-to-earnings-growth ratio of 3.04 and a beta of 1.28. Puma Biotechnology has a twelve month low of $2.13 and a twelve month high of $7.73.

Institutional Investors Weigh In On Puma Biotechnology

Large investors have recently made changes to their positions in the company. Crestline Management LP boosted its position in Puma Biotechnology by 6.5% during the fourth quarter. Crestline Management LP now owns 34,774 shares of the biopharmaceutical company's stock worth $151,000 after purchasing an additional 2,135 shares during the period. Boothbay Fund Management LLC boosted its position in shares of Puma Biotechnology by 19.8% in the first quarter. Boothbay Fund Management LLC now owns 24,229 shares of the biopharmaceutical company's stock valued at $75,000 after acquiring an additional 4,011 shares during the period. Federated Hermes Inc. boosted its position in shares of Puma Biotechnology by 1.2% in the third quarter. Federated Hermes Inc. now owns 355,368 shares of the biopharmaceutical company's stock valued at $842,000 after acquiring an additional 4,251 shares during the period. Geode Capital Management LLC boosted its position in shares of Puma Biotechnology by 1.2% in the second quarter. Geode Capital Management LLC now owns 396,396 shares of the biopharmaceutical company's stock valued at $1,399,000 after acquiring an additional 4,774 shares during the period. Finally, Jump Financial LLC boosted its position in shares of Puma Biotechnology by 26.6% in the third quarter. Jump Financial LLC now owns 24,690 shares of the biopharmaceutical company's stock valued at $65,000 after acquiring an additional 5,190 shares during the period. Institutional investors own 61.29% of the company's stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.